Literature DB >> 15863186

Primary malignant vaginal melanoma treated with adriamycin and ifosfamide: a case report and literature review.

M Signorelli1, A A Lissoni, A Garbi, P Perego, C Mangioni.   

Abstract

BACKGROUND: Vaginal melanoma is a very rare but highly malignant gynecological disease, usually diagnosed in postmenopausal woman. The prognosis tends to be poor and it is associated with high rate of recurrence and short survival rates. CASE: The following paper describes a case report regarding a 72-year-old woman with a locally advanced malignant melanoma. The previous erroneous histopathological diagnosis was leiomyosarcoma. She underwent chemotherapy with 3 courses of doxorubicin and ifosfamide. The diagnosis of malignant melanoma was obtained after a repeated biopsy and further pathological investigations. She later underwent radical surgery and 2 additional cycles of the same chemotherapy. At present, 7 months after the last cycle, the patient was locally disease-free, but developed brain metastases, requiring chemotherapy treatment.
CONCLUSION: In view of poor survival, this chemotherapy regimen may be an interesting alternative to the traditional treatment of vaginal melanoma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15863186     DOI: 10.1016/j.ygyno.2005.02.013

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  2 in total

Review 1.  [The primary melanoma of the female genital tract: report of three cases and review of literature].

Authors:  Amal Bennani; Hinde el Fatemi; Sanae Erraghay; Hind Mobakir; Hassania Ameurtess; Ihsane Souuaf; Kaoutar Moumna; Karima Idrissi; Asmae Zriouel; Nadia Squalli; Abdelaziz Banani; Affaf Amarti
Journal:  Pan Afr Med J       Date:  2013-10-19

2.  Vaginal primary malignant melanoma: a rare and aggressive tumor.

Authors:  Georgios Androutsopoulos; Emmanouil Terzakis; Georgia Ioannidou; Athanasios Tsamandas; Georgios Decavalas
Journal:  Case Rep Obstet Gynecol       Date:  2013-07-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.